drugset
drugset / Trial / NCT04866225

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

NCT04866225 ↗

Phase 1 Completed 6 enrolled Pfizer
Non-randomizedSequentialOpen-labelBasic science

Summary

This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose study of PF-06865571 in healthy male participants to characterize the ADME properties of \[14C\]PF-06865571 following oral administration; and to evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration of unlabeled PF-06865571 and IV administration of \[14C\]PF-06865571.

Timeline

Start
2021-05-11
Primary completion
2021-07-11
Completion
2021-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06865571 Small molecule — Oral

Indications

No indication recorded.